{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:45:05Z","timestamp":1788245105551,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CCSG P30 CA093373"],"award-info":[{"award-number":["CCSG P30 CA093373"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.clgc.2022.10.016","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T04:14:29Z","timestamp":1667535269000},"page":"203-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["ATR Inhibition in Advanced Urothelial Carcinoma"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4056-9651","authenticated-orcid":false,"given":"Ryan C.","family":"Leibrandt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Juan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Ming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Primo N.","family":"Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.10.016_bib0001","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2022.10.016_bib0002","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.10.016_bib0003","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.10.016_bib0004","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/cncr.23848","article-title":"A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience","volume":"113","author":"Dash","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.10.016_bib0005","unstructured":"Cancer Stat Facts: Bladder Cancer. NIH NCI: surveillance, epidemiology, and end results program. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. Published 2019. Accessed August 11, 2021."},{"issue":"1","key":"10.1016\/j.clgc.2022.10.016_bib0006","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ctrv.2013.03.002","article-title":"Targeting ATR in DNA damage response and cancer therapeutics","volume":"40","author":"Fokas","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2022.10.016_bib0007","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clgc.2022.10.016_bib0008","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.clgc.2022.10.016_bib0009","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.pharmthera.2013.12.010","article-title":"Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors","volume":"142","author":"Pitts","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clgc.2022.10.016_bib0010","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1007\/s00018-014-1666-4","article-title":"Functional interplay between ATM\/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress","volume":"71","author":"Yan","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clgc.2022.10.016_bib0011","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nature01368","article-title":"DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation","volume":"421","author":"Bakkenist","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2022.10.016_bib0012","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM\u2013Chk2 and ATR\u2013Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.clgc.2022.10.016_bib0013","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1073\/pnas.0611584104","article-title":"Cross-talk between Chk1 and Chk2 in double-mutant thymocytes","volume":"104","author":"Zaugg","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.clgc.2022.10.016_bib0014","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jmcb\/mju045","article-title":"CHK2 kinase in the DNA damage response and beyond","volume":"6","author":"Zannini","year":"2014","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.clgc.2022.10.016_bib0015","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1541-7786.MCR-14-0240","article-title":"A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function","volume":"13","author":"Menezes","year":"2015","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.clgc.2022.10.016_bib0016","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM-or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.clgc.2022.10.016_bib0017","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/pmic.201500172","article-title":"ATR inhibition rewires cellular signaling networks induced by replication stress","volume":"16","author":"Wagner","year":"2016","journal-title":"Proteomics"},{"key":"10.1016\/j.clgc.2022.10.016_bib0018","doi-asserted-by":"crossref","unstructured":"Wengner AM, Siemeister G, Luecking U, et\u00a0al. Synergistic in vivo activity of the ATR inhibitor BAY 1895344 in combination with the targeted alpha therapy radium-223 dichloride in a preclinical tumor model mimicking bone metastatic castration-resistant prostate cancer (mCRPC). 2018.","DOI":"10.1158\/1538-7445.AM2018-838"},{"key":"10.1016\/j.clgc.2022.10.016_bib0019","doi-asserted-by":"crossref","first-page":"16891","DOI":"10.18632\/oncotarget.24738","article-title":"ATM\/RB1 mutations predict shorter overall survival in urothelial cancer","volume":"9","author":"Yin","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2022.10.016_bib0020","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1634\/theoncologist.2019-0851","article-title":"Prognostic value of DNA damage response genomic alterations in relapsed\/advanced urothelial cancer","volume":"25","author":"Yin","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2022.10.016_bib0021","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association Between Smoking and Risk of Bladder Cancer Among Men and Women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2022.10.016_bib0022","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1126\/science.aag0299","article-title":"Mutational signatures associated with tobacco smoking in human cancer","volume":"354","author":"Alexandrov","year":"2016","journal-title":"Science (80-)"},{"key":"10.1016\/j.clgc.2022.10.016_bib0023","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00280-003-0571-6","article-title":"Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma","volume":"51","author":"Mack","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3B","key":"10.1016\/j.clgc.2022.10.016_bib0024","first-page":"2275","article-title":"Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin","volume":"23","author":"Yazlovitskaya","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2022.10.016_bib0025","doi-asserted-by":"crossref","first-page":"44289","DOI":"10.18632\/oncotarget.6247","article-title":"The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo","volume":"6","author":"Vendetti","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2022.10.016_bib0026","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.18632\/oncotarget.2158","article-title":"Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970","volume":"5","author":"Hall","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2022.10.016_bib0027","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.3892\/or.2017.5580","article-title":"Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine","volume":"37","author":"Liu","year":"2017","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clgc.2022.10.016_bib0028","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1535-7163.MCT-18-0010","article-title":"The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression","volume":"17","author":"Wallez","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2022.10.016_bib0029","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.10.016_bib0030","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaoncol.2021.3441","article-title":"Effect of cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma: a phase 2 randomized clinical trial","volume":"7","author":"Pal","year":"2021","journal-title":"JAMA Oncol"},{"issue":"13 Supplement","key":"10.1016\/j.clgc.2022.10.016_bib0031","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1538-7445.AM2019-369","article-title":"Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy","volume":"79","author":"Zenke","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2022.10.016_bib0032","doi-asserted-by":"crossref","unstructured":"De Bono JS, Tan DSP, Caldwell R, et\u00a0al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. 2019.","DOI":"10.1200\/JCO.2019.37.15_suppl.3007"},{"key":"10.1016\/j.clgc.2022.10.016_bib0033","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clgc.2022.10.016_bib0034","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.10.016_bib0035","first-page":"1307","article-title":"Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing","volume":"8","author":"Sun","year":"2018","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.clgc.2022.10.016_bib0036","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0959-8049(16)32607-7","article-title":"1LBA - Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers","volume":"69","author":"Yap","year":"2016","journal-title":"Eur J Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322002233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322002233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:37:34Z","timestamp":1761565054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322002233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1558767322002233"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.10.016","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATR Inhibition in Advanced Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}